Dyadic Highlights Increasing Interest In Proprietary C1 Protein Production Platform As Global Infectious Disease Preparedness Efforts Intensify In Response To Ongoing Bundibugyo Ebola Virus Outbreak

8-K filing — DYADIC INTERNATIONAL INC (DYAI)

Filed: 2026-08-14 AccNo: 0001493152-26-038039 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Dyadic International shares are trading lower after the company announced a $2.9 million offering and concurrent private placement.

Dyadic International Announces Definitive Agreements For $2.9M Registered Direct Offering And Concurrent Private Placement Of Warrants With Institutional Investor

Dyadic International, Inc. (NASDAQ:DYAI) (the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and nutrition,

Dyadic International shares are trading lower after the company reported worse-than-expected Q2 financial results.